Other
Amantadine
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Amantadine is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed9 · 50%
Unknown status6 · 33%
Terminated3 · 17%
Clinical Trials
Trial Activity
18 trials
Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness
Completed·—·N/A·NCT02025439·4 enrolled
Treatment of Huntington's Chorea With Amantadine
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00001930·25 enrolled
Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients
Completed·—·Phase 2/3·NCT03178708·60 enrolled
Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation
Terminated·—·Phase 4·NCT00975611·6 enrolled
Benefits of Amantadine in Patients With Coma State
Unknown status·—·N/A·NCT03443037·56 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)